To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Sponsored by Morelle, Joseph D. (Democrat-NY-25) · House · Introduced May 15, 2026
AI-assisted analysis: Summaries and rider analysis are generated using AI and reviewed for accuracy. This tool is for informational purposes only. Always verify with official sources before making decisions.Learn about our methodology.
Plain-English Summary (AI-assisted)
This bill would modify which engineered cyclic peptide drugs qualify for Medicare's Drug Price Negotiation Program. The change would affect which medications are eligible for federal price negotiations by adjusting the definition of 'qualifying single source drugs' within the program.
Legislative Status Timeline
Introduced
May 15, 2026
In Committee
May 15, 2026
Passed House
Pending
Passed Senate
Pending
Presidential Action
Pending
Sponsor
Morelle, Joseph D.
Independent · NY-25
Want to know when this bill's status changes?
Get notified about 119-hr-8857 and other NY legislation.